The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Relationship of baseline PSA and degree of PSA decline to radiographic progression-free survival (rPFS) in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC): Results from COU-AA-302.
Charles J. Ryan
Honoraria - Janssen
Anil Londhe
Employment or Leadership Position - Johnson & Johnson
Stock Ownership - Johnson & Johnson
Arturo Molina
Employment or Leadership Position - Johnson & Johnson
Stock Ownership - Johnson & Johnson
Matthew R. Smith
Consultant or Advisory Role - Johnson & Johnson
Research Funding - Johnson & Johnson
Johann Sebastian De Bono
Employment or Leadership Position - The Institute of Cancer Research
Consultant or Advisory Role - Astellas Pharma; Johnson & Johnson; Medivation
Honoraria - Astellas Pharma; Johnson & Johnson; Medivation
Peter Mulders
No relevant relationships to disclose
Dana E. Rathkopf
Research Funding - Johnson & Johnson
Fred Saad
Consultant or Advisory Role - Astellas Pharma; Janssen
Honoraria - Astellas Pharma; Janssen
Research Funding - Astellas Pharma; Janssen
Christopher Logothetis
Consultant or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; Johnson & Johnson; Novartis; Pfizer
Honoraria - Astellas Pharma; Bristol-Myers Squibb; Johnson & Johnson; Novartis; Pfizer
Research Funding - Astellas Pharma; Bristol-Myers Squibb; Johnson & Johnson; Novartis; Pfizer
Karim Fizazi
Consultant or Advisory Role - Janssen
Honoraria - Janssen
Howard I. Scher
Consultant or Advisory Role - Aragon Pharmaceuticals (U); Bristol-Myers Squibb; Celgene (U); Dendreon; Endo/Orion Pharmaceuticals; Exelixis (U); Foundation Medicine (U); Genentech; Janssen (U); Johnson & Johnson (U); Medivation (U); Millennium (U); Novartis; Ortho Biotech; Sanofi ; Senior Scientific; Takeda (U)
Research Funding - Aragon Pharmaceuticals; Bristol-Myers Squibb; Exelixis; Janssen; Janssen Research & Development; Medivation
Eric Jay Small
No relevant relationships to disclose
Shannon Matheny
Employment or Leadership Position - Janssen Research & Development
Stock Ownership - Johnson & Johnson
Thian San Kheoh
Employment or Leadership Position - Janssen
Stock Ownership - Johnson & Johnson
Thomas W. Griffin
Employment or Leadership Position - Johnson & Johnson
Stock Ownership - Johnson & Johnson